CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Status Recruiting

Clinical Trial Summary

This is a prospective, single arm, multicenter study to evaluate the safety and efficacy of CMOEP in patients with untreated peripheral T-cell lymphoma.

Clinical Trial Description

This is a single-arm, open label, multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with Cyclophosphamide, Vincristine, Etoposide and Prednisone(CMOEP) in patients with untreated Peripheral T-cell Lymphoma.Mitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mg/m2 and be combined with cyclophosphamide, vincristine, etoposide and prednisone.Each cycle consists of 21 days. A maximum of 6 cycles of therapy are planned. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06433362
Study type	Interventional
Source	Tianjin Medical University Cancer Institute and Hospital
Contact	Jingwei Yu
Phone	86-15022015208
Email	jingweiyu@pku.org.cn
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2024
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT04390737` - Evaluate the Safety and Clinical Activity of HH2853	Phase 1/Phase 2
Recruiting	`NCT05559008` - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes	Phase 1/Phase 2
Recruiting	`NCT06083701` - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study	Phase 1/Phase 2
Not yet recruiting	`NCT02856997` - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04083495` - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma	Phase 2
Not yet recruiting	`NCT05979792` - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma	Early Phase 1
Recruiting	`NCT04984837` - Study of Lacutamab in Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT06072131` - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL	Phase 3
Completed	`NCT01716806` - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	Phase 2
Terminated	`NCT03947255` - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma	Phase 2
Recruiting	`NCT04028440` - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)	Early Phase 1
Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
Recruiting	`NCT05883449` - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL	Phase 2
Active, not recruiting	`NCT03586999` - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT04489264` - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting	`NCT06151106` - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma	Phase 2
Recruiting	`NCT02753543` - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma	Phase 2
Not yet recruiting	`NCT06089941` - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas